Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Embecta Corp. (EMBC) : This medical device company has seen the Zacks Consensus Estimate for its current year earnings increasing 14.9% over the last 60 days.Toast, Inc. (TOST) : This cloud-based digital technology platform provider has seen the Zacks Consensus Estimate for its current year earnings increasing 120% over the last 60 days.monday.com Ltd. (MNDY) : This software development company has seen the Zacks Consensus Estimate for ...

Financial Data and Key Metrics Changes - In Q4 2024, Embecta's adjusted revenues totaled $290.2 million, representing a 4.1% increase compared to the prior year period, or 3.3% excluding contract manufacturing revenue [40] - For the full year 2024, adjusted revenues were approximately $1,127 million, reflecting a 1.1% increase on an adjusted constant currency basis [45] - Adjusted EBITDA for Q4 2024 was approximately $73 million, with a margin of 25.2%, compared to $79.6 million and 28.2% in the prior year [59] - GAAP net income for Q4 2024 was $14.6 million, or $0.25 per diluted share, compared to $6 million and $0.10 in the prior year [57] Business Line Data and Key Metrics Changes - Pen needle revenue grew approximately 2.8%, syringe revenue grew approximately 4.8%, safety products grew approximately 5.8%, and contract manufacturing grew approximately 96% in Q4 2024 [41] - For the full year, pen needle and safety product lines grew approximately 2.6% and 2.5%, respectively, while syringe product lines declined approximately 9% [46] Market Data and Key Metrics Changes - International revenue in Q4 totaled $122.8 million, a 3.1% decline on an adjusted constant currency basis, primarily due to timing of orders in China and the impact of the Italian payback measure [43] - U.S. revenues for the full year totaled $607.2 million, an increase of 1% on an adjusted constant currency basis, driven by favorable pricing dynamics [47] Company Strategy and Development Direction - The company announced a restructuring plan aimed at streamlining operations and reducing costs, including the discontinuation of the insulin patch pump program [16] - Future strategic priorities include strengthening the core business, expanding the product portfolio, and increasing financial flexibility [24] - The company plans to focus on GLP-1 therapies and has launched a new small pack pen needle product in Germany [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced, including historic inflation and supply chain issues, which impacted margins by approximately 500 basis points [14] - The company anticipates that pricing will become a headwind in 2025 due to the renewal of agreements [49] - Management expressed confidence in the company's ability to navigate the evolving market landscape and capitalize on growth opportunities [96] Other Important Information - The company incurred approximately $63 million in expenses related to the patch pump program during fiscal year 2024 [73] - A debt paydown plan was initiated to enhance financial flexibility moving forward [15] Q&A Session Summary Question: Inquiry about capital allocation priorities post patch pump decision - Management emphasized that the primary focus is on debt paydown to create financial flexibility for potential M&A opportunities [87][88] Question: Clarification on potential impacts from tariffs and macroeconomic factors - Management noted that a small portion of U.S. revenue comes from products manufactured in China and will monitor tariff developments closely [96] Question: Discussion on residual value of the patch pump and future opportunities - Management stated that while no viable options surfaced for monetizing the patch pump, they remain open to future discussions if interest arises [114] Question: Inquiry about cost savings from restructuring - Management confirmed that the restructuring is primarily tied to the discontinuation of the patch pump, aligning with the anticipated savings [116]

| --- | --- | |------------------------------|-------| | | | | | | | | | | Earnings Conference Call | | | | | | Fiscal Q4 and Full Year 2024 | | | | | | November 26, 2024 | | Forward-Looking Statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations reg ...

On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.The company reported quarterly sales of $286.1 million, up 1.5% year over year, beating the consensus of $277 million.“We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics…Additionally, the recent launch of our small-pack GLP-1 needle ...

Exhibit 99.1 Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs PARSIPPANY, N.J., November 26, 2024 (GLOBE NEWSWIRE) – Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. "We are ...

PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. "We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics. We continued to execute on our strategic priorities, and to date, our significant accomplishment ...

Core Viewpoint - Embecta Corp. will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, along with preliminary financial guidance for fiscal year 2025 on November 26, 2024 [1]. Group 1: Company Overview - Embecta is a global diabetes care company with a 100-year legacy in insulin delivery, focused on empowering people with diabetes through innovative solutions and partnerships [3]. - The company employs over 2,000 individuals worldwide, emphasizing its commitment to improving the lives of those with diabetes [3]. Group 2: Conference Call Details - The conference call is scheduled for 8:00 a.m. Eastern Time (ET) on November 26, 2024, and will be accessible via a live webcast and teleconference [1][2]. - A replay of the call will be available starting at 11:00 a.m. ET on the same day and will be archived for one year on the company's investor relations website [2].

Group 1 - Embecta Corp. will host a conference call on November 26, 2024, at 8:00 a.m. ET to discuss its fiscal fourth quarter and full year 2024 financial results, along with preliminary fiscal year 2025 financial guidance [1] - Participants can access the live webcast through the company's website or via a teleconference link, with a replay available starting November 21, 2024 [2] - Embecta is a global diabetes care company with a 100-year legacy in insulin delivery, focusing on empowering people with diabetes through innovative solutions and partnerships [3]

Core Insights - Embecta Corp. has received FDA 510(k) clearance for its disposable patch pump designed for insulin delivery, marking a significant advancement in diabetes care for Type 2 diabetes (T2D) patients [1][2] - The new insulin delivery system is expected to enhance Embecta's market position by addressing the unmet needs of T2D patients, a segment historically underserved by existing insulin pump technologies [2][10] Company Developments - The newly approved system features a 300-unit insulin reservoir, which is sufficient for 64% of T2D patients over three days, compared to only 38% for a 200-unit reservoir [6] - The system includes a user-friendly interface with Bluetooth technology and a color touchscreen, facilitating the transition from multiple daily injections to pump therapy for T2D patients [7] - Embecta is also developing a closed-loop version of the insulin delivery system, which will incorporate an advanced insulin-dosing algorithm for improved convenience and precision [9] Market Performance - Embecta's shares have increased by 22.2% over the past six months, significantly outperforming the industry growth of 2.9% and the S&P 500 Index's gain of 11.7% during the same period [4] - Following the FDA clearance announcement, EMBC stock gained 0.7% on September 3, indicating positive investor sentiment [2] Strategic Positioning - The FDA clearance reflects Embecta's commitment to innovation and its strategic goals, leveraging its 100-year legacy in diabetes care to establish itself as a leader in the field [8][10] - The company aims to expand its product offerings and improve the quality of life for individuals with diabetes, particularly focusing on the underserved T2D population [10]

Core Insights - Embecta Corp has received FDA 510(k) clearance for its disposable insulin delivery system, aimed at adults with diabetes, including both T1D and T2D [1][2] - The system features a tubeless patch pump with a 300-unit insulin reservoir, designed specifically for T2D patients transitioning from multiple daily injections to pump therapy [1][2] - The patch pump can deliver adjustable basal and bolus insulin for up to three days, addressing the higher daily insulin needs of T2D patients [2][4] Product Features - The disposable insulin delivery system includes a wearable patch pump that can accommodate higher insulin requirements, with 64% of T2D adults able to use the 300-unit reservoir for three days, compared to only 38% with a 200-unit reservoir [2] - The system is equipped with a locked-down controller featuring Bluetooth technology and a color touchscreen for a simplified user experience [3] Strategic Importance - Achieving FDA clearance is a strategic priority for Embecta, reflecting its commitment to improving the lives of people with diabetes [2] - The company plans to develop a closed-loop version of the patch pump, which will include an insulin-dosing algorithm for future FDA submission [4] Company Background - Embecta is a global diabetes care company with a 100-year legacy in insulin delivery, focusing on innovative solutions to empower individuals with diabetes [6]